Linear Source Registry for Prostate Cancer

CivaTech Oncology60 enrolled

Overview

Ongoing follow up for subjects implanted with the Linear Source String for prostate cancer.

This registry is being conducted to provide long term analysis on the use of the linear Civastring source for prostate cancer. Prospective data collection will record and demonstrate biochemical response rates. Long term side effects and adverse events will be monitored.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostate Cancer

Interventions

Linear LDR SourceRADIATION

The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years old * Plans to remain in care of enrolling physician for 5 years * \> 5 years life expectancy * Signed informed consent * Enrolled within 6 weeks of implant or within 365 days of prior implant Exclusion Criteria: * Not willing or able to comply with protocol visit schedule

Locations (3)

Chicago Prostate Cancer Center

Chicago, Illinois, United States

Manhattan Medical Researcch

New York, New York, United States

Bon Secours DePaul Medical Center

Norfolk, Virginia, United States

Outcomes

Primary Outcomes

Biochemical Response Rate (PSA)

Time frame: Up to 5 years

Secondary Outcomes

Side Effects (IPSS, IIEF, RFAS score)

Time frame: Up to 5 years

Adverse Events

Time frame: Up to 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.